Showing results (631-640 of 700) with videos related to

Sort By:
Pageof 70
British Journal of Cancer|April 19, 2023
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2Denise G O'Mahony, Susan J Ramus, Melissa C Southey, et al.
Nature Communications|July 5, 2020
Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancersYan Dora Zhang, Amber N Hurson, Haoyu Zhang, et al.
Breast Cancer Research : BCR|November 13, 2016
Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 womenTimothy R Rebbeck, Tara M Friebel, Nandita Mitra, et al.
Medrxiv : the Preprint Server for Health Sciences|September 16, 2024
Analysis of more than 400,000 women provides case-control evidence for BRCA1 and BRCA2 variant classificationMaria Zanti, Denise G O'Mahony, Michael T Parsons, et al.
British Journal of Cancer|June 7, 2012
Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter studyA Jakubowska, D Rozkrut, A Antoniou, et al.
Nature Communications|May 24, 2025
Analysis of more than 400,000 women provides case-control evidence for BRCA1 and BRCA2 variant classificationMaria Zanti, Denise G O'Mahony, Michael T Parsons, et al.
Human Molecular Genetics|September 6, 2011
Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriersDavid G Cox, Jacques Simard, Daniel Sinnett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2011
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testingPaul D P Pharoah, Rachel T Palmieri, Susan J Ramus, et al.
Human Genetics|May 21, 2011
Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriersKate M Im, Tomas Kirchhoff, Xianshu Wang, et al.
Breast (Edinburgh, Scotland)|November 12, 2025
Large-scale meta-analysis and precision functional assays identify FANCM regions in which PTVs confer different risks for ER-negative and triple-negative breast cancerAmandine Billaud, Gisella Figlioli, Clémence Mooser, et al.
Pageof 70